Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stelios Therapeutics, Inc.

Latest From Stelios Therapeutics, Inc.

Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies

The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.

Financing Gene Therapy

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deals M & A

PainReform licenses Encore's post-surgical pain product

The pain management company PainReformhas entered into its first major licence agreement by signing a deal withEncore Therapeutics, which gives the Israeli firm exclusive North American rights to Encore's post-surgical pain product, ETI-211, as well as the option to expand the agreement to other countries including Japan and the EU.

Neurology Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • GenStem Therapeutics, Inc.
UsernamePublicRestriction

Register